PT2999715T - Novo anticorpo útil em distúrbios neurológicos ou neurodegenerativos - Google Patents
Novo anticorpo útil em distúrbios neurológicos ou neurodegenerativosInfo
- Publication number
- PT2999715T PT2999715T PT147311633T PT14731163T PT2999715T PT 2999715 T PT2999715 T PT 2999715T PT 147311633 T PT147311633 T PT 147311633T PT 14731163 T PT14731163 T PT 14731163T PT 2999715 T PT2999715 T PT 2999715T
- Authority
- PT
- Portugal
- Prior art keywords
- neurological
- neurodegenerative disorders
- antibody useful
- novel antibody
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13002641 | 2013-05-21 | ||
| EP13002850.9A EP2805972A1 (en) | 2013-05-21 | 2013-06-03 | Novel antibody useful in neurological or neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2999715T true PT2999715T (pt) | 2021-03-24 |
Family
ID=48463678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT147311633T PT2999715T (pt) | 2013-05-21 | 2014-05-21 | Novo anticorpo útil em distúrbios neurológicos ou neurodegenerativos |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10072077B2 (pt) |
| EP (2) | EP2805972A1 (pt) |
| JP (2) | JP6865581B2 (pt) |
| DK (1) | DK2999715T3 (pt) |
| ES (1) | ES2855973T3 (pt) |
| PT (1) | PT2999715T (pt) |
| WO (1) | WO2014187879A2 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10583171B2 (en) | 2015-11-30 | 2020-03-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | NMDAR antagonists for the treatment of diseases associated with angiogenesis |
| CN110606887A (zh) * | 2019-08-12 | 2019-12-24 | 陕西脉元生物科技有限公司 | 人体液中抗nmdar自身抗体的检测材料、制备方法及应用 |
| AU2021281828A1 (en) | 2020-05-27 | 2023-02-02 | Arialys Therapeutics, Inc. | Anti-human NR1 antibody derivative |
| WO2024026420A1 (en) * | 2022-07-29 | 2024-02-01 | Arialys Therapeutics, Inc. | Methods and systems for identifying or treating central nervous systems disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7858752B2 (en) * | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| EP2289542A1 (en) | 2009-08-31 | 2011-03-02 | PAION Deutschland GmbH | Treatment of neurological or neurodegenerative disorders |
-
2013
- 2013-06-03 EP EP13002850.9A patent/EP2805972A1/en not_active Ceased
-
2014
- 2014-05-21 JP JP2016514405A patent/JP6865581B2/ja active Active
- 2014-05-21 US US14/890,613 patent/US10072077B2/en active Active
- 2014-05-21 ES ES14731163T patent/ES2855973T3/es active Active
- 2014-05-21 PT PT147311633T patent/PT2999715T/pt unknown
- 2014-05-21 EP EP14731163.3A patent/EP2999715B1/en active Active
- 2014-05-21 DK DK14731163.3T patent/DK2999715T3/da active
- 2014-05-21 WO PCT/EP2014/060486 patent/WO2014187879A2/en active Application Filing
-
2018
- 2018-08-09 US US16/059,469 patent/US20180371082A1/en not_active Abandoned
-
2019
- 2019-07-19 JP JP2019133416A patent/JP2019201655A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10072077B2 (en) | 2018-09-11 |
| US20160115230A1 (en) | 2016-04-28 |
| JP6865581B2 (ja) | 2021-04-28 |
| EP2999715B1 (en) | 2020-12-23 |
| WO2014187879A3 (en) | 2015-01-22 |
| EP2999715A2 (en) | 2016-03-30 |
| WO2014187879A2 (en) | 2014-11-27 |
| ES2855973T3 (es) | 2021-09-27 |
| JP2019201655A (ja) | 2019-11-28 |
| DK2999715T3 (da) | 2021-03-29 |
| EP2805972A1 (en) | 2014-11-26 |
| JP2016531085A (ja) | 2016-10-06 |
| US20180371082A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1257261A1 (zh) | 抗fcrh5抗體 | |
| HK1217023A1 (zh) | 新型抗體 | |
| PL3003473T3 (pl) | Miejscowa stymulacja neurologiczna | |
| EP2987125A4 (en) | LINKED ADVERTISING CONTENT | |
| GB201318071D0 (en) | Transaction personalisation | |
| GB201322583D0 (en) | Antibodies | |
| HRP20181336T1 (hr) | Vozilo tipa zakretnog klatna | |
| HK1199504A1 (en) | Tourbillon | |
| GB201312279D0 (en) | Neurodegenerative disorders | |
| HK1220142A1 (zh) | 抗體 | |
| GB201308658D0 (en) | Antibodies | |
| GB2558188B (en) | Vehicle track element | |
| HK1214795A1 (zh) | 汽車 | |
| GB201315486D0 (en) | Antibodies | |
| GB201300706D0 (en) | Antibody | |
| IL245488A0 (en) | Anti- ccl17 antibodies | |
| EP3002588A4 (en) | Biomarker for psychiatric and neurological disorders | |
| PT2999715T (pt) | Novo anticorpo útil em distúrbios neurológicos ou neurodegenerativos | |
| GB2516629B (en) | Interactive vehicles | |
| EP2927243A4 (en) | ANTI-VASOHIBIN ANTIBODY-2 | |
| GB201310041D0 (en) | Road stud | |
| SG11201604503XA (en) | Cytotoxic antibody | |
| GB201414199D0 (en) | Vehicle mounted pollutant precipitator | |
| HU4492U (en) | Additional spiral spring for vehicles | |
| GB201312303D0 (en) | Concept Car 1 |